Chemexpress(688131) 华金证券·2024-11-27 12:23Investment Rating - The report assigns an investment rating of AA-/AA- to the company and its convertible bond issuance [9][11]. Core Viewpoints - The company is a leading integrated enterprise in the research and production of small molecule drugs, focusing on providing comprehensive services from drug discovery to commercial production [15][16]. - The issuance of the convertible bond is aimed at raising funds for various projects, including high-end pharmaceutical intermediates and raw materials, which are expected to yield significant economic benefits [59][60][61]. Summary by Sections Convertible Bond Analysis - The total issuance size of the convertible bond is 822 million yuan, with a term of 6 years and a conversion price set at 40.73 yuan per share [9][10]. - The bond features a high compensation interest rate of 11%, and the dilution rates for total and circulating shares are 8.74% and 8.92%, respectively, indicating minimal dilution pressure [10][11]. Stock Analysis - The company is primarily focused on providing CRO and CDMO services for the global pharmaceutical and biopharmaceutical industries, with a strong emphasis on small molecule and new molecular drug development [15][16]. - As of November 2024, the company has a net asset return (ROE) of 5.49%, which is higher than the average of comparable companies [53]. Financial Analysis - For the first nine months of 2024, the company achieved an operating income of 1.619 billion yuan, a year-on-year increase of 17.65%, and a net profit of 143 million yuan, up 21.31% year-on-year [39][43]. - The company maintains a reasonable level of liquidity, with current and quick ratios indicating strong short-term debt repayment capabilities [44]. Valuation Performance - As of November 26, 2024, the company's price-to-earnings ratio (PE) is 52.44, which is below the average of comparable companies, indicating high valuation elasticity [53]. - The company's stock price has increased by 2.69% year-to-date, outperforming the industry index, which has decreased by 11.46% [53]. Fundraising Project Analysis - The funds raised will be allocated to several projects, including the construction of production facilities for high-end pharmaceutical intermediates and raw materials, which are projected to have a significant internal rate of return [59][60][61].